Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding

Heavy menstrual bleeding affects approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists. About 23 million women in the U.S. sought care from a healthcare professional for the condition last year, underscoring a substantial unmet healthcare need.